News
One million parents turn to virtual baby advice as online classes grow in popularity
Digital platform supports parents through live interactive online classes
Prenatal and postnatal virtual education provider The Baby Academy has announced plans for expansion after its digital platform reached one million users.
The service, supported by International Board-Certified Lactation Consultants (IBCLCs), is aimed at providing personalised support for parents who want to learn and develop their skills in baby care, safety and first aid, breastfeeding, weaning and sleep.
The platform provides standard information and education via its live interactive online classes to users across Ireland, the UK, US and Canada.
The aim, the founders say, is to empower modern-day parents to make the best decisions for their baby’s development.
The platform features a team of 85 healthcare professionals, who guide new and expectant parents throughout the vital stages of their baby’s early development. Areas of focus include lactation, baby safety and first aid as well as perinatal mental health.
The World Health Organisation recommends the implementation of digital services into how healthcare is delivered as an integral way to ensure the vision of the global strategy to improve healthcare for everyone is achieved.
With the global digital health market in 2022 valued at £175bn and market predictions expecting it to continue to grow at a compound annual growth rate (CAGR) of 18.6 per cent from 2023 to 2030, The Baby Academy founders are now focused on expansion.
Brian McGovern, co-founder of The Baby Academy, said: “We are thrilled to cross the milestone of one million registered users of the Baby Academy.
“I believe the platform’s success is indicative of the potential for technology to deliver healthcare in new ways, and also of the need for additional support for new parents at a time when they are commencing their parenting journey.
“We are proud to support them during this time, and look forward to further growth in 2023 and beyond.”
The milestone follows the unveiling of the company’s one-to-one breastfeeding consultation service and the announcement of its £2.6 million funding round.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







Pingback: Empowerment through education: how virtual classes can support women on their motherhood journey - FemTech World